Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2155062 | 0.86 | MAPT (0.63) | MAPTSMN1; SMN2RAB9ANPC1CYP1A2 | |
| SCHEMBL21707908 | 0.85 | TSHR (0.48) | MAPTSMN1; SMN2RAB9ANPC1CYP1A2 | |
| SCHEMBL2155094 | 0.85 | MAPT (0.66) | MAPTSMN1; SMN2RAB9ANPC1CYP1A2 | |
| SCHEMBL22749339 | 0.85 | MAPT (0.52) | MAPTSMN1; SMN2RAB9ANPC1CYP1A2 | |
| SCHEMBL21707917 | 0.84 | MAPT (0.44) | MAPTSMN1; SMN2RAB9ANPC1CYP1A2 | |
| SCHEMBL4255397 | 0.84 | TDP1 (0.55) | MAPTSMN1; SMN2RAB9ANPC1CYP1A2 | |
| SCHEMBL29204387 | 0.83 | ALDH1A1 (0.51) | MAPTSMN1; SMN2RAB9ALMNAALDH1A1 | |
| SCHEMBL21707869 | 0.83 | MAPT (0.58) | MAPTSMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL8991985 | 0.82 | ALDH1A1 (0.50) | MAPTSMN1; SMN2RAB9ALMNAALDH1A1 | |
| SCHEMBL8381526 | 0.82 | L3MBTL1 (0.58) | MAPTLMNAALDH1A1L3MBTL1SIRT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360085-A1 | Glucose Uptake Inhibitors | KADMON CORPORATION, LLC (US) | 2024-10-31 | — | — | US | disclosed |
| US-12030857-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030857-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030857-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2024-07-09 | — | — | US | disclosed |
| US-20220363648-A1 | Glucose Uptake Inhibitors | KADMON CORPORATION, LLC | 2022-11-17 | — | — | US | disclosed |
| US-11071735-B2 | Treatment of inflammatory conditions and autoimmune diseases with glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2021-07-27 | — | — | US | disclosed |
| US-11071735-B2 | Treatment of inflammatory conditions and autoimmune diseases with glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2021-07-27 | — | — | US | disclosed |
| US-20200046702-A1 | TREATMENT OF INFLAMMATORY CONDITIONS AND AUTOIMMUNE DISEASES WITH GLUCOSE UPTAKE INHIBITORS | KADMON CORPORATION, LLC | 2020-02-13 | — | — | US | disclosed |
| US-20200046702-A1 | TREATMENT OF INFLAMMATORY CONDITIONS AND AUTOIMMUNE DISEASES WITH GLUCOSE UPTAKE INHIBITORS | KADMON CORPORATION, LLC | 2020-02-13 | — | — | US | disclosed |
| WO-2018201006-A1 | TREATMENT OF INFLAMMATORY CONDITIONS AND AUTOIMMUNE DISEASES WITH GLUCOSE UPTAKE INHIBITORS | KADMON CORPORATION, LLC (US) | 2018-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030857-B2 | Glucose uptake inhibitors | SLC2A1, SLC2A4, SLC2A2 | MAPT 1835/4885SMN1; SMN2 3766/4885RAB9A 1581/4885 |
| US-20220363648-A1 | Glucose Uptake Inhibitors | SLC2A1, SLC2A4, SLC2A2 | MAPT 1835/4885SMN1; SMN2 3766/4885RAB9A 1581/4885 |
| US-11071735-B2 | Treatment of inflammatory conditions and autoimmune diseases with glucose uptake inhibitors | SLC2A3, SLC2A4, SLC2A1 | MAPT 1704/4885SMN1; SMN2 3512/4885RAB9A 1218/4885 |
| US-20200046702-A1 | TREATMENT OF INFLAMMATORY CONDITIONS AND AUTOIMMUNE DISEASES WITH GLUCOSE UPTAKE INHIBITORS | SLC2A3, SLC2A4, SLC2A1 | MAPT 1704/4885SMN1; SMN2 3512/4885RAB9A 1218/4885 |
| US-20240360085-A1 | Glucose Uptake Inhibitors | SLC2A3, SLC2A1, SLC2A4 | MAPT 1717/4885SMN1; SMN2 3677/4885RAB9A 1198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.